BAT 1006
Alternative Names: BAT-1006Latest Information Update: 28 Mar 2025
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (IV, Injection)
- 17 Jun 2024 Bio-Thera Solutions completes phase I trial in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05414136)
- 08 May 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) (NCT06376136)